Laurence Collette
Statistics Department
European Organisation for Research and Treatment of Cancer Data Center
Brussels
Belgium
Name/email consistency: high
- Patients with curative resection of cT3-4 rectal cancer after preoperative radiotherapy or radiochemotherapy: does anybody benefit from adjuvant fluorouracil-based chemotherapy? A trial of the European Organisation for Research and Treatment of Cancer Radiation Oncology Group. Collette, L., Bosset, J.F., den Dulk, M., Nguyen, F., Mineur, L., Maingon, P., Radosevic-Jelic, L., Piérart, M., Calais, G. J. Clin. Oncol. (2007)
- Prostate-specific antigen (PSA) alone is not an appropriate surrogate marker of long-term therapeutic benefit in prostate cancer trials. Collette, L., Burzykowski, T., Schröder, F.H. Eur. J. Cancer (2006)
- Is prostate-specific antigen a valid surrogate end point for survival in hormonally treated patients with metastatic prostate cancer? Joint research of the European Organisation for Research and Treatment of Cancer, the Limburgs Universitair Centrum, and AstraZeneca Pharmaceuticals. Collette, L., Burzykowski, T., Carroll, K.J., Newling, D., Morris, T., Schröder, F.H. J. Clin. Oncol. (2005)
- Patients at high risk of progression after radical prostatectomy: do they all benefit from immediate post-operative irradiation? (EORTC trial 22911). Collette, L., van Poppel, H., Bolla, M., van Cangh, P., Vekemans, K., Da Pozzo, L., de Reijke, T.M., Verbaeys, A., Bosset, J.F., Piérart, M. Eur. J. Cancer (2005)